Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$1.2 million.

  • Contineum Therapeutics' Change in Account Payables fell 28416.29% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$653000.0, marking a year-over-year decrease of 57318.84%. This contributed to the annual value of $1.1 million for FY2024, which is N/A changed from last year.
  • Contineum Therapeutics' Change in Account Payables amounted to -$1.2 million in Q3 2025, which was down 28416.29% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Change in Account Payables registered a high of $1.8 million during Q1 2025, and its lowest value of -$1.6 million during Q2 2025.
  • Its 3-year average for Change in Account Payables is $10000.0, with a median of $170000.0 in 2024.
  • Over the last 5 years, Contineum Therapeutics' Change in Account Payables had its largest YoY gain of 272000.0% in 2025, and its largest YoY loss of 106705.88% in 2025.
  • Contineum Therapeutics' Change in Account Payables (Quarter) stood at -$625000.0 in 2023, then skyrocketed by 160.48% to $378000.0 in 2024, then tumbled by 423.02% to -$1.2 million in 2025.
  • Its Change in Account Payables was -$1.2 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $1.8 million in Q1 2025.